Vandeputte C, Bregni G, Gkolfakis P, et al. - Considering the toxicity burden associated with regorafenib in the treatment of refractory metastatic colorectal cancer (mCRC), researchers investigated predictive factors for treatment-related adverse events (TRAEs). They analyzed 136 patients who had taken regorafenib (160 mg/day, 3-weeks-on/1-week-off) in a prospective phase II clinical trial. Gender was revealed to be the only independent predictive factor of early and any-time toxicity; females more frequently suffered grade ≥2 TRAEs during the first cycle of treatment as well as grade ≥3 TRAEs throughout the whole treatment. A significantly more frequent report of fatigue, anorexia, hypertension, and rash was made by females vs males. For the first time ever, a link was evident between gender and TRAEs during regorafenib treatment for mCRC in this study.